| Stage | CTAS | % of rev | OXM | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $3.0B | 100.00% | $394M | 100.00% | CTAS ×7.64 |
| Gross profit | $1.6B | 51.54% | $291M | 73.82% | OXM +22.3pp |
| Operating income | $712M | 23.62% | $69M | 17.45% | CTAS +6.2pp |
| Pre-tax income | $690M | 22.89% | $67M | 17.07% | CTAS +5.8pp |
| Net income | $552M | 18.31% | $49M | 12.42% | CTAS +5.9pp |
| Stage | CTAS | OXM | Gap · A − B |
|---|---|---|---|
| Revenue | $3.0B100.00% | $394M100.00% | CTAS ×7.64 |
| Gross profit | 51.54%$1.6B | 73.82%$291M | OXM +22.3pp |
| Operating income | 23.62%$712M | 17.45%$69M | CTAS +6.2pp |
| Pre-tax income | 22.89%$690M | 17.07%$67M | CTAS +5.8pp |
None
No disclosed counterparties: CTAS.
| Net income |
| 18.31%$552M |
| 12.42%$49M |
| CTAS +5.9pp |